Jim Simons Halozyme Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 255,280 shares of HALO stock, worth $11.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

255,280

Previous 377,580 32.39%

Holding current value

$11.7 Million

Previous $19.8 Million 26.13%

% of portfolio

0.02%

Previous 0.03%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$51.3 - $64.42 $6.27 Million - $7.88 Million	-122,300 Reduced 32.39%	255,280 $14.6 Million
Q2 2024 Aug 09, 2024	SELL	$37.81 - $52.4 $2.03 Million - $2.82 Million	-53,800 Reduced 12.47%	377,580 $19.8 Million
Q1 2024 May 13, 2024	BUY	$33.68 - $41.95 $8.02 Million - $9.98 Million	238,000 Added 123.07%	431,380 $17.5 Million
Q4 2023 Feb 13, 2024	BUY	$33.32 - $42.1 $2.92 Million - $3.69 Million	87,700 Added 82.99%	193,380 $7.15 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $2.61 Million - $3.15 Million	71,600 Added 210.09%	105,680 $4.04 Million
Q2 2023 Aug 11, 2023	SELL	$30.28 - $38.74 $1.85 Million - $2.37 Million	-61,061 Reduced 64.18%	34,080 $1.23 Million
Q1 2023 May 12, 2023	SELL	$32.86 - $55.7 $1.53 Million - $2.59 Million	-46,500 Reduced 32.83%	95,141 $3.63 Million
Q4 2022 Feb 13, 2023	SELL	$40.06 - $59.44 $8.68 Million - $12.9 Million	-216,659 Reduced 60.47%	141,641 $8.06 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $4.89 Million - $6.57 Million	-126,900 Reduced 26.15%	358,300 $14.2 Million
Q2 2022 Aug 12, 2022	BUY	$37.35 - $48.3 $10.4 Million - $13.4 Million	277,500 Added 133.61%	485,200 $21.3 Million
Q1 2022 May 13, 2022	BUY	$31.97 - $41.06 $2.61 Million - $3.35 Million	81,700 Added 64.84%	207,700 $8.28 Million
Q4 2021 Feb 11, 2022	SELL	$31.82 - $40.75 $865,504 - $1.11 Million	-27,200 Reduced 17.75%	126,000 $5.07 Million
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $5.89 Million - $7.11 Million	153,200 New	153,200 $6.23 Million
Q2 2021 Aug 13, 2021	SELL	$38.84 - $51.31 $26.2 Million - $34.6 Million	-673,700 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$39.51 - $51.45 $5.75 Million - $7.49 Million	145,571 Added 27.56%	673,700 $28.1 Million
Q4 2020 Feb 10, 2021	BUY	$25.81 - $43.62 $11,072 - $18,712	429 Added 0.08%	528,129 $22.6 Million
Q3 2020 Nov 13, 2020	SELL	$25.74 - $29.63 $12.4 Million - $14.2 Million	-480,500 Reduced 47.66%	527,700 $13.9 Million
Q2 2020 Aug 13, 2020	BUY	$16.25 - $26.81 $11.1 Million - $18.4 Million	684,800 Added 211.75%	1,008,200 $27 Million
Q1 2020 May 14, 2020	SELL	$13.9 - $21.83 $12.4 Million - $19.5 Million	-895,200 Reduced 73.46%	323,400 $5.82 Million
Q4 2019 Feb 13, 2020	BUY	$14.93 - $19.53 $18.2 Million - $23.8 Million	1,218,600 New	1,218,600 $21.6 Million
Q3 2019 Nov 13, 2019	SELL	$15.2 - $17.69 $6.97 Million - $8.11 Million	-458,600 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$14.75 - $17.26 $4.29 Million - $5.02 Million	-290,800 Reduced 38.8%	458,600 $7.88 Million
Q1 2019 May 14, 2019	BUY	$13.94 - $17.58 $6.2 Million - $7.82 Million	444,800 Added 146.03%	749,400 $12.1 Million
Q4 2018 Feb 13, 2019	BUY	$13.33 - $18.66 $4.06 Million - $5.68 Million	304,600 New	304,600 $4.46 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.37B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account